Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorRocha, Ana T.
dc.creatorPaiva, Edison F.
dc.creatorLichtenstein, Arnaldo
dc.creatorMilani Jr., Rodolfo
dc.creatorCavalheiro-Filho, Cyrillo
dc.creatorMaffei, Francisco Humberto de Abreu
dc.date2014-05-27T11:22:37Z
dc.date2016-10-25T18:24:26Z
dc.date2014-05-27T11:22:37Z
dc.date2016-10-25T18:24:26Z
dc.date2007-10-16
dc.date.accessioned2017-04-06T01:26:59Z
dc.date.available2017-04-06T01:26:59Z
dc.identifierVascular Health and Risk Management, v. 3, n. 4, p. 533-553, 2007.
dc.identifier1176-6344
dc.identifierhttp://hdl.handle.net/11449/69939
dc.identifierhttp://acervodigital.unesp.br/handle/11449/69939
dc.identifier10.2147/VHRM.S
dc.identifier2-s2.0-35048898109.pdf
dc.identifier2-s2.0-35048898109
dc.identifierhttp://dx.doi.org/10.2147/VHRM.S
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/891107
dc.descriptionThe risk for venous thromboembolism (VTE) in medical patients is high, but risk assessment is rarely performed because there is not yet a good method to identify candidates for prophylaxis. Purpose: To perform a systematic review about VTE risk factors (RFs) in hospitalized medical patients and generate recommendations (RECs) for prophylaxis that can be implemented into practice. Data sources: A multidisciplinary group of experts from 12 Brazilian Medical Societies searched MEDLINE, Cochrane, and LILACS. Study selection: Two experts independently classified the evidence for each RF by its scientific quality in a standardized manner. A risk-assessment algorithm was created based on the results of the review. Data synthesis: Several VTE RFs have enough evidence to support RECs for prophylaxis in hospitalized medical patients (eg, increasing age, heart failure, and stroke). Other factors are considered adjuncts of risk (eg, varices, obesity, and infections). According to the algorithm, hospitalized medical patients ≥40 years-old with decreased mobility, and ≥1 RFs should receive chemoprophylaxis with heparin, provided they don't have contraindications. High prophylactic doses of unfractionated heparin or low-molecular-weight-heparin must be administered and maintained for 6-14 days. Conclusions: A multidisciplinary group generated evidence-based RECs and an easy-to-use algorithm to facilitate VTE prophylaxis in medical patients. © 2007 Rocha et al, publisher and licensee Dove Medical Press Ltd.
dc.languageeng
dc.relationVascular Health and Risk Management
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectEmbolism and thrombosis
dc.subjectGuideline
dc.subjectHeparin
dc.subjectPrevention and control
dc.subjectRisk factors
dc.subjectRisk-assessment
dc.subjectantineoplastic agent
dc.subjectdalteparin
dc.subjectenoxaparin
dc.subjectestrogen
dc.subjectfondaparinux
dc.subjectgestagen
dc.subjectheparin
dc.subjecthormone
dc.subjectlow molecular weight heparin
dc.subjectnadroparin
dc.subjectplacebo
dc.subjectrecombinant erythropoietin
dc.subjecttamoxifen
dc.subjectthalidomide
dc.subjectwarfarin
dc.subjectacute heart infarction
dc.subjectage distribution
dc.subjectcancer
dc.subjectcancer chemotherapy
dc.subjectcancer hormone therapy
dc.subjectcentral venous catheterization
dc.subjectcerebrovascular accident
dc.subjectclinical protocol
dc.subjectclinical trial
dc.subjectcompression therapy
dc.subjectcongestive heart failure
dc.subjectdeep vein thrombosis
dc.subjectdrug dosage form comparison
dc.subjectdrug dose comparison
dc.subjectdrug efficacy
dc.subjectdrug megadose
dc.subjectenteritis
dc.subjectevidence based medicine
dc.subjecthormonal contraception
dc.subjecthormone substitution
dc.subjecthospital patient
dc.subjecthuman
dc.subjecthyperhomocysteinemia
dc.subjectimmobilization
dc.subjectinfection
dc.subjectischemic heart disease
dc.subjectlow drug dose
dc.subjectlung embolism
dc.subjectnephrotic syndrome
dc.subjectobesity
dc.subjectparesis
dc.subjectperipheral vascular disease
dc.subjectpregnancy
dc.subjectpuerperium
dc.subjectrespiratory tract disease
dc.subjectreview
dc.subjectrheumatic disease
dc.subjectrheumatoid arthritis
dc.subjectrisk assessment
dc.subjectrisk factor
dc.subjectSwan Ganz catheter
dc.subjectsystematic review
dc.subjectsystemic lupus erythematosus
dc.subjectthrombophilia
dc.subjectthrombophlebitis
dc.subjectthrombosis prevention
dc.subjectvenous thromboembolism
dc.subjectAlgorithms
dc.subjectHumans
dc.subjectRisk Assessment
dc.subjectThromboembolism
dc.titleRisk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients
dc.typeOtro


Este ítem pertenece a la siguiente institución